Yee, A., O'Donnell, E., Nadeem, O., Nelson, G., Wildes, T., Buck, T., Tuchman, S., Ghimire, K., Sinclair, S., Stewart, C., Richardson, P., Usmani, S., Raje, N. (2025). A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41). Blood. https://doi.org/10.1182/blood-2025-4053